BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) today announced an $85 million contribution to the Gilead Foundation to further the company’s vision of creating a healthier world for all people.

Greene LLP announces that the international pharmaceutical company, Biogen, Inc, has agreed to pay $900 million to resolve claims brought by Michael Bawduniak, a client of Greene LLP, that Biogen unlawfully paid kickbacks to physicians and other healthcare professionals.

LEO Pharma A/S, a global leader in medical dermatology, today announced that American Journal of Clinical Dermatology published 32-week results from a post-hoc analysis of the Phase 3 ECZTRA 3 clinical trial (NCT03363854) in atopic dermatitis (AD).

Enveda Biosciences, a pioneer in small molecule drug discovery using machine learning and metabolomics to harness the potential of natural products, announced that Tobias Kind, Ph.D., will join the company’s industry-leading data science team as Research Fellow.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Wednesday, August 3rd, at 4:30 p.m. ET to discuss second quarter 2022 financial results and provide a general business update.

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or “the Company”), today announced that the Company has entered into a Sponsored Research Agreement (the “SRA”) with Cincinnati Children’s Hospital Medical Center (“Cincinnati Children’s”) to explore vaccine development of its norovirus shell and protrusion (S&P) platform for multiple diseases.

Nexus Spine, a developer of biomechanically-advanced solutions for spinal pathologies, today announced the beta launch of its Stable-C™ cervical interbody fusion implants featuring integrated anchoring blades.

Today, Wellspring Ophthalmics, a Mission Viejo-based development stage eye care pharmaceutical company focused on innovating an improved, effective dry eye therapy, announces receiving its second patent for a novel cyclosporine dry eye therapy.

The bioanalytical services market is expected to grow at a CAGR of 8.2% during the forecast period 2022 to 2030.

The cardiovascular proximal anastomosis devices market is slated to clock a favorable CAGR of ~6% during the assessment period.